Cargando…

Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease

BACKGROUND: Vascular risk factors have been associated with differences in cognitive performance in epidemiological studies, but evidence in patients with coronary heart disease is more limited. METHODS AND RESULTS: The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Ralph A. H., Held, Claes, Krug‐Gourley, Sue, Waterworth, Dawn, Stebbins, Amanda, Chiswell, Karen, Hagstrom, Emil, Armstrong, Paul W., Wallentin, Lars, White, Harvey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509727/
https://www.ncbi.nlm.nih.gov/pubmed/30897999
http://dx.doi.org/10.1161/JAHA.118.010641
_version_ 1783417301943451648
author Stewart, Ralph A. H.
Held, Claes
Krug‐Gourley, Sue
Waterworth, Dawn
Stebbins, Amanda
Chiswell, Karen
Hagstrom, Emil
Armstrong, Paul W.
Wallentin, Lars
White, Harvey
author_facet Stewart, Ralph A. H.
Held, Claes
Krug‐Gourley, Sue
Waterworth, Dawn
Stebbins, Amanda
Chiswell, Karen
Hagstrom, Emil
Armstrong, Paul W.
Wallentin, Lars
White, Harvey
author_sort Stewart, Ralph A. H.
collection PubMed
description BACKGROUND: Vascular risk factors have been associated with differences in cognitive performance in epidemiological studies, but evidence in patients with coronary heart disease is more limited. METHODS AND RESULTS: The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization to darapladib, a reversible inhibitor of lipoprotein phospholipase A(2) or placebo was evaluated for 10 634 patients with coronary heart disease from 38 countries in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. The Montreal Cognitive Assessment scores for darapladib and placebo groups were similar (mean±SD, 25.3±3.84 versus 25.4±3.73, respectively; P=0.27) and the adjusted odds ratio (OR) for mild cognitive impairment (Montreal Cognitive Assessment score <26) was 1.00 (95% CI, 0.93–1.09). Mild cognitive impairment was more likely with increasing age (OR, 1.33 [1.27–1.41], +5 years after 65). For other baseline clinical characteristics, the strongest independent predictors of cognitive impairment were education (≤8 years versus college/university, OR, 2.95 [2.60–3.35]; >8 years/trade school versus college/university, OR, 1.38 [1.25–1.52] and geographic grouping). Cardiovascular risk factors independently associated with cognitive impairment were history of stroke (OR, 1.43 [1.20–1.71]); <2.5 hours of moderate or vigorous intensity exercise/week (OR, 1.19 [1.04–1.37]); high‐density lipoprotein cholesterol <1.16 mmol/L (OR, 1.19 [1.04–1.37]); diabetes mellitus requiring treatment (OR, yes versus no: 1.15 [1.05–1.26]); and history of hypertension (OR, 1.12 [1.02–1.23]). CONCLUSIONS: In patients with stable coronary heart disease, cognitive performance was associated with modifiable cardiovascular risk factors, educational level, and global region, but was not influenced by darapladib. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00799903.
format Online
Article
Text
id pubmed-6509727
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65097272019-05-20 Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease Stewart, Ralph A. H. Held, Claes Krug‐Gourley, Sue Waterworth, Dawn Stebbins, Amanda Chiswell, Karen Hagstrom, Emil Armstrong, Paul W. Wallentin, Lars White, Harvey J Am Heart Assoc Original Research BACKGROUND: Vascular risk factors have been associated with differences in cognitive performance in epidemiological studies, but evidence in patients with coronary heart disease is more limited. METHODS AND RESULTS: The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization to darapladib, a reversible inhibitor of lipoprotein phospholipase A(2) or placebo was evaluated for 10 634 patients with coronary heart disease from 38 countries in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. The Montreal Cognitive Assessment scores for darapladib and placebo groups were similar (mean±SD, 25.3±3.84 versus 25.4±3.73, respectively; P=0.27) and the adjusted odds ratio (OR) for mild cognitive impairment (Montreal Cognitive Assessment score <26) was 1.00 (95% CI, 0.93–1.09). Mild cognitive impairment was more likely with increasing age (OR, 1.33 [1.27–1.41], +5 years after 65). For other baseline clinical characteristics, the strongest independent predictors of cognitive impairment were education (≤8 years versus college/university, OR, 2.95 [2.60–3.35]; >8 years/trade school versus college/university, OR, 1.38 [1.25–1.52] and geographic grouping). Cardiovascular risk factors independently associated with cognitive impairment were history of stroke (OR, 1.43 [1.20–1.71]); <2.5 hours of moderate or vigorous intensity exercise/week (OR, 1.19 [1.04–1.37]); high‐density lipoprotein cholesterol <1.16 mmol/L (OR, 1.19 [1.04–1.37]); diabetes mellitus requiring treatment (OR, yes versus no: 1.15 [1.05–1.26]); and history of hypertension (OR, 1.12 [1.02–1.23]). CONCLUSIONS: In patients with stable coronary heart disease, cognitive performance was associated with modifiable cardiovascular risk factors, educational level, and global region, but was not influenced by darapladib. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00799903. John Wiley and Sons Inc. 2019-03-22 /pmc/articles/PMC6509727/ /pubmed/30897999 http://dx.doi.org/10.1161/JAHA.118.010641 Text en © 2019 The Authors and GlaxoSmithKline. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Stewart, Ralph A. H.
Held, Claes
Krug‐Gourley, Sue
Waterworth, Dawn
Stebbins, Amanda
Chiswell, Karen
Hagstrom, Emil
Armstrong, Paul W.
Wallentin, Lars
White, Harvey
Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
title Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
title_full Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
title_fullStr Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
title_full_unstemmed Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
title_short Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
title_sort cardiovascular and lifestyle risk factors and cognitive function in patients with stable coronary heart disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509727/
https://www.ncbi.nlm.nih.gov/pubmed/30897999
http://dx.doi.org/10.1161/JAHA.118.010641
work_keys_str_mv AT stewartralphah cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT heldclaes cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT kruggourleysue cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT waterworthdawn cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT stebbinsamanda cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT chiswellkaren cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT hagstromemil cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT armstrongpaulw cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT wallentinlars cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease
AT whiteharvey cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease